Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores
Liver International · 2026-11 · 46 (11)
DOI: 10.1111/liv.70909 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Liver International, online erschienen am 06.10.2026. Verfasst von Bernardo Stefanini und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Bevacizumab, Carcinoma, Hepatocellular, Cardiovascular Diseases. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background & Aims The management of comorbidities has become increasingly relevant in unresectable hepatocellular carcinoma (uHCC) as immunotherapy prolongs survival. Atezolizumab plus bevacizumab (AB) is a standard first‐line option, but bevacizumab carries a risk of cardiovascular toxicities. Data on cardiovascular risk stratification in patients with cirrhosis remain limited. Identifying patients at increased cardiovascular risk is therefore clinically important, particularly given the availability of bevacizumab‐free alternatives.
Methods
We retrospectively analysed prospectively collected data from the multicenter Italian ARTE database, including patients with uHCC treated with first‐line AB between June 2022 and July 2025. Traditional major adverse cardiovascular events (tMACE) were defined as acute coronary syndromes, heart failure, cerebrovascular events, or peripheral ischemia, while an extended composite (eMACE) additionally included venous thromboembolism and immune‐related myocarditis. Cardiovascular risk was stratified using the European Society of Cardiology (ESC) Cardio‐Oncology classification and the CARDIOSOR score. Competing‐risk analyses were performed considering treatment discontinuation as a competing event.
Results
This study included 538 patients (median age 69.8 years). During follow‐up, 20 patients (3.7%) experienced tMACE, and 30 (5.6%) experienced eMACE. Patients assigned to the very high‐risk category by ESC criteria and those with a high‐risk CARDIOSOR score had a significantly increased risk of tMACE and eMACE. Both scores demonstrated a moderate ability to stratify cardiovascular risk (Harrell's c‐index 0.68 for ESC and 0.59 for CARDIOSOR).
Conclusions
Cardiovascular adverse events were uncommon overall, but their incidence was not negligible in patients in high‐risk subgroups. Risk scores may help identify vulnerable subgroups and support patient‐tailored treatment strategies, including consideration of bevacizumab‐free regimens in selected cases. Trial Registration Multicenter ARTE database (NCT06806579)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Hepatopancreatobiliary Oncology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Division of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
- Department of Pathophysiology and Transplantation, CRC 'A. M. and A. Migliavacca' Centre for Liver Disease, University of Milan, Milan, Italy.
- Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy.
ORCID-Profile: Bernardo Stefanini, Lorenza Rimassa, Massimo Iavarone, Giuseppe Cabibbo, Fabio Marra, Andrea Dalbeni, Sara Lonardi, Lorenzo Lani, Piera Federico, Tiziana Pressiani, Mariangela Bruccoleri, Alessandra Auriemma, Leonardo Stella, Pierluigi Toniutto, Rosanna Villani, Sara Ascari, Mariarosaria Marseglia, Alessandro Granito, Fabio Piscaglia, Francesco Tovoli
Zitieren
APA
Stefanini, B., Rimassa, L., Iavarone, M., Cabibbo, G., Marra, F., Vivaldi, C., Dalbeni, A., Ponziani, F. R., Palloni, A., Lonardi, S., Lani, L., Federico, P., Svegliati-Baroni, G., Pressiani, T., Ielasi, L., Mazzarelli, C., De Lorenzo, S., Sacco, R., Bruccoleri, M., …, & ARTE Study Group (2026). Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores. Liver International, 46(11). https://doi.org/10.1111/liv.70909
Vancouver
Stefanini B, Rimassa L, Iavarone M, Cabibbo G, Marra F, Vivaldi C, et al. Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores. Liver International. 2026;46(11). doi:10.1111/liv.70909
BibTeX
@article{Stefanini2026,
author = {Stefanini, Bernardo and Rimassa, Lorenza and Iavarone, Massimo and Cabibbo, Giuseppe and Marra, Fabio and Vivaldi, Caterina and Dalbeni, Andrea and Ponziani, Francesca Romana and Palloni, Andrea and Lonardi, Sara and Lani, Lorenzo and Federico, Piera and Svegliati-Baroni, Gianluca and Pressiani, Tiziana and Ielasi, Luca and Mazzarelli, Chiara and De Lorenzo, Stefania and Sacco, Rodolfo and Bruccoleri, Mariangela and Celsa, Ciro and Mastro, Alessio and Masi, Gianluca and Auriemma, Alessandra and Stella, Leonardo and Toniutto, Pierluigi and Villani, Rosanna and Deiana, Chiara and Ascari, Sara and Marseglia, Mariarosaria and Granito, Alessandro and Piscaglia, Fabio and Tovoli, Francesco and ARTE Study Group, ARTE Study Group},
title = {Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores},
journal = {Liver International},
year = {2026},
volume = {46},
number = {11},
doi = {10.1111/liv.70909}
}
EUVIMED